NZ504291A - Compositions and methods for targeted delivery of factors - Google Patents

Compositions and methods for targeted delivery of factors

Info

Publication number
NZ504291A
NZ504291A NZ504291A NZ50429198A NZ504291A NZ 504291 A NZ504291 A NZ 504291A NZ 504291 A NZ504291 A NZ 504291A NZ 50429198 A NZ50429198 A NZ 50429198A NZ 504291 A NZ504291 A NZ 504291A
Authority
NZ
New Zealand
Prior art keywords
factors
compositions
methods
targeted delivery
bound
Prior art date
Application number
NZ504291A
Inventor
Lawrence Tamarkin
Giulio F Paciotti
Original Assignee
Cytimmune Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/966,940 external-priority patent/US6274552B1/en
Application filed by Cytimmune Sciences Inc filed Critical Cytimmune Sciences Inc
Publication of NZ504291A publication Critical patent/NZ504291A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Abstract

A composition comprising one or more effector molecules and one or more cell-specific targeting molecules bound to a colloidal metal platform, wherein at least one molecule is bound to the platform indirectly via an integrating molecule.
NZ504291A 1997-11-10 1998-11-10 Compositions and methods for targeted delivery of factors NZ504291A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/966,940 US6274552B1 (en) 1993-03-18 1997-11-10 Composition and method for delivery of biologically-active factors
US7581198P 1998-02-24 1998-02-24
US8669698P 1998-05-26 1998-05-26
US10745598P 1998-11-06 1998-11-06
PCT/US1998/023931 WO1999024077A2 (en) 1997-11-10 1998-11-10 Compositions and methods for targeted delivery of biologically-active factors

Publications (1)

Publication Number Publication Date
NZ504291A true NZ504291A (en) 2002-10-25

Family

ID=27491221

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ504291A NZ504291A (en) 1997-11-10 1998-11-10 Compositions and methods for targeted delivery of factors

Country Status (9)

Country Link
US (1) US20090035265A1 (en)
EP (1) EP1044022B1 (en)
JP (1) JP4620243B2 (en)
AT (1) ATE320270T1 (en)
AU (1) AU760035B2 (en)
CA (1) CA2309604C (en)
DE (1) DE69833876T2 (en)
NZ (1) NZ504291A (en)
WO (1) WO1999024077A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010055581A1 (en) 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
NZ504292A (en) * 1997-11-10 2003-03-28 Cytimmune Sciences Inc Methods and compositions for enhancing immune response using a targeted delivery system and for the production of in vitro mabs
US7229841B2 (en) * 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US6407218B1 (en) 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
JP2009286808A (en) * 1997-11-10 2009-12-10 Cytimmune Sciences Inc Composition and method for targeted delivery of biologically-active factors
AU2002259107B2 (en) * 2001-04-30 2006-10-26 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
CA2548179A1 (en) * 2003-12-02 2005-07-21 Cytimmune Sciences, Inc. Methods and compositions for the production of monoclonal antibodies
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
US8877156B2 (en) 2007-06-26 2014-11-04 New York University Contrast agents anchored by thiols on nanoparticles
KR20100123674A (en) * 2007-09-21 2010-11-24 싸이티뮨 사이언스, 인크. Nanotherapeutic colloidal metal compositions and methods
CA2706700A1 (en) 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
KR20140001257A (en) 2008-05-13 2014-01-06 유니버시티 오브 캔사스 Metal abstraction peptide(map) tag and associated methods
US9187735B2 (en) 2012-06-01 2015-11-17 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
US10064940B2 (en) 2013-12-11 2018-09-04 Siva Therapeutics Inc. Multifunctional radiation delivery apparatus and method

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963354A (en) * 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
US5047523A (en) * 1988-08-02 1991-09-10 Ortho Diagnostic Systems Inc. Nucleic acid probe for detection of neisseria gonorrhoea
US5248772A (en) * 1992-01-29 1993-09-28 Coulter Corporation Formation of colloidal metal dispersions using aminodextrans as reductants and protective agents
AU6414994A (en) * 1993-03-18 1994-10-11 Cytimmune Sciences, Inc. Composition and method for reducing toxicity of biologically-active factors
JPH07227299A (en) * 1994-02-14 1995-08-29 Kyoto Daiichi Kagaku:Kk Method for detecting specific base sequence of dna and device therefor
US5521289A (en) * 1994-07-29 1996-05-28 Nanoprobes, Inc. Small organometallic probes
US5686578A (en) * 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
EP0837696B1 (en) * 1995-06-07 2010-02-24 Immunomedics, Inc. Improved delivery of diagnostic and therapeutic agents to a target site
ES2210514T3 (en) * 1996-04-10 2004-07-01 Sangstat Medical Corporation SPECIFIC UNION COUPLE MEMBER CYCLING CONJUGATES
DE19622628A1 (en) * 1996-06-05 1997-12-11 Boehringer Mannheim Gmbh Stabilization of metal conjugates
CA2262006A1 (en) * 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
WO1998050435A1 (en) * 1997-05-02 1998-11-12 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunotoxins, comprising an onc protein, directed against malignant cells
DE19726186A1 (en) * 1997-06-20 1998-12-24 Boehringer Ingelheim Int Complexes for the transport of nucleic acid into higher eukaryotic cells
EP1715971A4 (en) * 2004-01-28 2010-10-13 Cytimmune Sciences Inc Functionalized colloidal metal compositions and methods
US20060185027A1 (en) * 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression

Also Published As

Publication number Publication date
JP2001522818A (en) 2001-11-20
CA2309604C (en) 2010-01-12
EP1044022A2 (en) 2000-10-18
DE69833876D1 (en) 2006-05-11
DE69833876T2 (en) 2007-05-24
JP4620243B2 (en) 2011-01-26
AU1394099A (en) 1999-05-31
US20090035265A1 (en) 2009-02-05
WO1999024077A3 (en) 1999-10-07
EP1044022B1 (en) 2006-03-15
WO1999024077A2 (en) 1999-05-20
CA2309604A1 (en) 1999-05-20
ATE320270T1 (en) 2006-04-15
AU760035B2 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
NZ504291A (en) Compositions and methods for targeted delivery of factors
ATE247470T1 (en) NEW SUBSTITUTED IMIDAZOLE COMPOUNDS
MY114014A (en) Imidazole compounds, compositions and use
PT935465E (en) NEW IMIDAZOLE REPLACED COMPOUNDS
CA2413190A1 (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
AU1718400A (en) Method for treating pain
DK1144472T3 (en) Aqueous reactive putties (II)
BG104315A (en) Prostaglandine agonists and their application for the treatment of osteal diseases
AU1270599A (en) Radioactive embolizing compositions
EP1131465A4 (en) Antisense modulation of interleukin-15 expression
AU690315B2 (en) Metal complexes with charged linker
EP1093819A3 (en) Compounds and compositions for delivering active agents
UA85993C2 (en) Conjugate of a bacterial superantigen and antibody moiety, pharmaceutical composition containing thereof and method for treatment of cancer in mammals
IL140437A0 (en) Pharmaceutical compositions comprising 2-quinolines
MX9603570A (en) Method and compositions for increasing the serum half-life of pharmacologically active agents.
DE69838979D1 (en) RECOMBINANT ANTIBODIES AND IMMUNOCONJUGATES TARGETED ON CD22-CARRYING CELLS AND TUMORS
AU2001290706A1 (en) Antisense modulation of clusterin expression
IL129592A0 (en) 5-HT1f agonists
AU9102198A (en) Indole-3-carbinol, diindolylmethane and substituted analogs as antiestrogens
ATE359825T1 (en) J-CHAIN AND ANALOGUE FOR CONJUGATES TARGETED TO EPITHELIAL CELLS
WO2003072754A3 (en) Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
NO20015785D0 (en) In its essential oil-free cyclosporin compositions
EP1123414A4 (en) Antisense modulation of integrin alpha 4 expression
GR3024667T3 (en) Cosmetical or pharmaceutical compositions comprising deacylated glycerophospholipids for topical use.
CA2296560A1 (en) Amino acid derivatives useful to treat stroke

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired